Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | FBP1 | P09467 | 2/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.32 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.32 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.32 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8682014 | 0.83 | AR (0.52) | ARNR1H2MEN1KMT2AMAPT | |
| SCHEMBL6288482 | 0.79 | AR (0.42) | ARNR1H2MEN1KMT2AMAPT | |
| SCHEMBL26229838 | 0.79 | AR (0.40) | ARNR1H2MEN1KMT2AMAPT | |
| SCHEMBL27837232 | 0.78 | — | — | |
| SCHEMBL31478751 | 0.77 | ALDH1A1 (0.39) | ARNR1H2MEN1KMT2AMAPT | |
| SCHEMBL577437 | 0.77 | — | — | |
| SCHEMBL22624207 | 0.75 | AR (0.39) | ARNR1H2MEN1KMT2AMAPT | |
| SCHEMBL8682794 | 0.73 | ALDH1A1 (0.40) | ARNR1H2ALDH1A1TSHRNOS1 | |
| SCHEMBL30756417 | 0.73 | — | — | |
| SCHEMBL8447549 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4157853-A1 | GUT MICROBIOTA BIOACTIVATED PDE4 INHIBITOR PRECURSORS | Giiant Pharma Inc. (CA) | 2023-04-05 | — | — | EP | disclosed |
| EP-1272488-B1 | TRI-ARYL-SUBSTITUTED-ETHANE PDE4 INHIBITORS | MERCK FROSST CANADA INC (CA) | 2006-03-22 | — | — | EP | disclosed |
| US-6841564-B2 | Tri-aryl-substituted-ethane PDE4 inhibitors | MERCK FROSST CANADA & CO. (CA) | 2005-01-11 | — | — | US | disclosed |
| US-6639077-B2 | Ethanes substituted with a phenyl, a thiazole, and a pyridyl are phosphodiesterase (PDE4) inhibitors; leukotriene receptor antagonists | MERCK FROSST CANADA & CO. (CA) | 2003-10-28 | — | — | US | disclosed |
| US-20020173661-A1 | Tri-aryl-substituted-ethane PDE4 inhibitors | MERCK FROSST CANADA & CO. | 2002-11-21 | — | — | US | disclosed |
| US-20020156105-A1 | Tri-aryl-substituted-ethane PDE4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2002-10-24 | — | — | US | disclosed |
| US-6399636-B2 | FOR THERAPY OF ASTHMA, CHRONIC BRONCHITIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), EOSINOPHILIC GRANULOMA, PSORIASIS AND SEPTIC SHOCK, ULCERATIVE COLITIS, CROHN'S DISEASE, REPERFUSION INJURY OF THE MYOCARDIUM AND BRAIN | MERCK FROSST CANADA & CO. (CA) | 2002-06-04 | — | — | US | disclosed |
| US-20020013347-A1 | Tri-aryl-substituted-ethane PDE4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2002-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173661-A1 | Tri-aryl-substituted-ethane PDE4 inhibitors | PDE4A, PDE4B, PDE3A | AR 213/4885NR1H2 2475/4885MEN1 3961/4885 |
| US-20020156105-A1 | Tri-aryl-substituted-ethane PDE4 inhibitors | PDE4A, PDE4B, PDE3A | AR 213/4885NR1H2 2475/4885MEN1 3961/4885 |
| US-20020013347-A1 | Tri-aryl-substituted-ethane PDE4 inhibitors | PDE4A, PDE4B, PDE3A | AR 256/4885NR1H2 3042/4885MEN1 3632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.